Skip to content
ppharmaranks
Menu
Class IIOngoing

GE Healthcare Omnipaque (iohexol) Injection recall

FDA recall D-0448-2026 · initiated Mar 24, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Apr 15, 2026How we research

GE Healthcare Ireland Limited recalled GE Healthcare Omnipaque (iohexol) Injection in Mar 2026 — an FDA Class II recall (D-0448-2026) because Presence of particulate matter.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Presence of particulate matter

Something got into the product

A physical or chemical contaminant was found — glass or metal fragments, or a solvent that should not be there.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot# 17333197; Exp. December 10, 2028 Lot# 17333198; Exp. November 17, 2028 Lot# 17396945; Exp. December 18, 2028 Lot# 17396948; Exp. December 22, 2028 Lot# 17396953; Exp. January 11, 2029 Lot# 17396956; Exp. January 9, 2029 Lot# 17423503; Exp. January 1, 2029 Lot# 17423525; Exp. January 3, 2029 Lot# 17426429; Exp. January 1, 2029 Lot# 17426440; Exp. January 4, 2029 Lot# 17431310; Exp. January 11, 2029

Quantity recalled: 306,810 vials

Details

Product
GE Healthcare Omnipaque (iohexol) Injection, 350 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1414-91.
Recalling company
GE Healthcare Ireland Limited
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
U.S. Nationwide.
Initiated
Mar 24, 2026
FDA report date
Apr 15, 2026

This recall is linked to a product we cover: Omnipaque 9

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was GE Healthcare Omnipaque (iohexol) Injection recalled?
GE Healthcare Ireland Limited recalled GE Healthcare Omnipaque (iohexol) Injection in Mar 2026 — an FDA Class II recall (D-0448-2026) because Presence of particulate matter. May cause temporary or medically reversible harm; low probability of serious harm.
Why was GE Healthcare Omnipaque (iohexol) Injection recalled?
Per the FDA enforcement record, the reason for recall D-0448-2026 was: Presence of particulate matter
Is a recalled GE Healthcare Omnipaque (iohexol) Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of GE Healthcare Omnipaque (iohexol) Injection are affected?
Distributed: U.S. Nationwide.. The recall covers these lots — Lot# 17333197; Exp. December 10, 2028 Lot# 17333198; Exp. November 17, 2028 Lot# 17396945; Exp. December 18, 2028 Lot# 17396948; Exp. December 22, 2028 Lot# 17396953; Exp. January 11, 2029 Lot# 17396956; Exp. January 9, 2029 Lot# 17423503; Exp. January 1, 2029 Lot# 17423525; Exp. January 3, 2029 Lot# 17426429; Exp. Jan…. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0448-2026.

Source: openFDA Drug Enforcement record D-0448-2026

← All drug recalls